Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults

ClinicalTrials.gov ID: NCT03100058

Public ClinicalTrials.gov record NCT03100058. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Dose-finding Study to Evaluate the Change in Weight After 24 Weeks Treatment With 8 Doses of LIK066 Compared to Placebo in Obese or Overweight Adults, Followed by 24 Weeks Treatment With 2 Doses of LIK066 and Placebo

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This was a dose-finding study that evaluated the change in weight after 24 weeks treatment with 8 different doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 weeks treatment with 2 doses of LIK066 and placebo.

Study identification

NCT ID
NCT03100058
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
460 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 5, 2017
Primary completion
Mar 1, 2018
Completion
Aug 1, 2018
Last update posted
Feb 5, 2020

2017 – 2018

United States locations

U.S. sites
59
U.S. states
24
U.S. cities
55
Facility City State ZIP Site status
Novartis Investigative Site Anniston Alabama 36207
Novartis Investigative Site Jasper Alabama 35501
Novartis Investigative Site Beverly Hills California 90211
Novartis Investigative Site Carmichael California 95608
Novartis Investigative Site Concord California 94520
Novartis Investigative Site Los Angeles California 90017
Novartis Investigative Site Northridge California 91325
Novartis Investigative Site Roseville California 95661
Novartis Investigative Site San Ramon California 94582
Novartis Investigative Site Stockton California 95204
Novartis Investigative Site Walnut Creek California 94598
Novartis Investigative Site Denver Colorado 80246
Novartis Investigative Site Golden Colorado 80401
Novartis Investigative Site Bradenton Florida 34209
Novartis Investigative Site Fort Lauderdale Florida 33312
Novartis Investigative Site Port Charlotte Florida 33952
Novartis Investigative Site West Palm Beach Florida 33401
Novartis Investigative Site Athens Georgia 30606
Novartis Investigative Site Augusta Georgia 30909
Novartis Investigative Site Honolulu Hawaii 96814
Novartis Investigative Site Gurnee Illinois 60031
Novartis Investigative Site Springfield Illinois 62711
Novartis Investigative Site Wauconda Illinois 60084
Novartis Investigative Site Evansville Indiana 47713
Novartis Investigative Site Evansville Indiana 47714
Novartis Investigative Site Indianapolis Indiana 46260
Novartis Investigative Site Louisville Kentucky 40213
Novartis Investigative Site Baton Rouge Louisiana 70808
Novartis Investigative Site Covington Louisiana 70433
Novartis Investigative Site Hammond Louisiana 70403
Novartis Investigative Site Metairie Louisiana 70006
Novartis Investigative Site New Orleans Louisiana 70115
Novartis Investigative Site New Orleans Louisiana 70119
Novartis Investigative Site Baltimore Maryland 21229
Novartis Investigative Site Beltsville Maryland 20705
Novartis Investigative Site Towson Maryland 21204
Novartis Investigative Site Royal Oak Michigan 48073
Novartis Investigative Site City of Saint Peters Missouri 63303
Novartis Investigative Site St Louis Missouri 63128
Novartis Investigative Site Missoula Montana 59808
Novartis Investigative Site Omaha Nebraska 68134
Novartis Investigative Site New York New York 10016
Novartis Investigative Site New York New York 10021
Novartis Investigative Site The Bronx New York 10455
Novartis Investigative Site Hickory North Carolina 28601
Novartis Investigative Site Lansdale Pennsylvania 19446
Novartis Investigative Site Pittsburgh Pennsylvania 15212
Novartis Investigative Site Moncks Corner South Carolina 29464
Novartis Investigative Site Mt. Pleasant South Carolina 29464
Novartis Investigative Site Summerville South Carolina 29485
Novartis Investigative Site Houston Texas 77081
Novartis Investigative Site Bountiful Utah 84010
Novartis Investigative Site Salt Lake City Utah 84102
Novartis Investigative Site Newport News Virginia 23606
Novartis Investigative Site Richmond Virginia 23235
Novartis Investigative Site Richmond Virginia 23294
Novartis Investigative Site Renton Washington 98057
Novartis Investigative Site Tacoma Washington 98405
Novartis Investigative Site Kenosha Wisconsin 53144

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03100058, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 5, 2020 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03100058 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →